Trials / Completed
CompletedNCT00422552
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol
An Exploratory, Double-Blind Comparison of Inspiratory Capacity (IC) and FEV1 in COPD Patients Following Single Dose Administration of Indacaterol and Placebo and Open Label b.i.d. Administration of Formoterol
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the change in inspiratory capacity and lung function in patients with chronic obstructive pulmonary disease when treated with indacaterol compared to placebo and formoterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indacaterol (QAB149) |
Timeline
- Start date
- 2006-09-01
- First posted
- 2007-01-17
- Last updated
- 2007-06-22
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00422552. Inclusion in this directory is not an endorsement.